Skip to main content
. 2016 Aug 25;6:32258. doi: 10.1038/srep32258

Figure 1. Down-regulation of SerpinB2 in gefitinib-resistant lung cancer cells.

Figure 1

(a) Cells were lysed, and SerpinB2 levels were analysed by western blot with an antibody against SerpinB2 and using β-actin as a loading control. (b) The mRNA levels of SERPINB2 were examined using real-time PCR. The data are presented as the mean fold changes ± SD relative to the H292 control. (c) Immunohistochemical analysis of SerpinB2 was performed using an anti-SerpinB2 antibody in tumor tissue sections obtained from a previous study. Scale bar, 50 μm. (d,e) Cells were treated with 100 nM gefitinib for 24 h and then SerpinB2 and uPA protein (d) and mRNA (e) levels were detected by western blot and real-time PCR, respectively. The data are presented as the mean fold changes ± SD relative to the vehicle-treated control. (f) SERPINB2 and UPA mRNA expression was examined using real-time PCR. The data are presented as the mean fold changes ± SD relative to the MRC-5 control. (g) SERPINB2 and UPA mRNA levels are presented as the mean fold changes ± SD relative to SERPINB2 expression of indicated cells. β-actin mRNA levels were used for normalization of real-time PCR data. *P < 0.05, **P < 0.01, ***P < 0.005.